Decline in Serum Cholinesterase Activities Predicts 2-Year Major Adverse Cardiac Events
Open Access
- 24 December 2013
- journal article
- Published by Springer Nature in Molecular Medicine
- Vol. 20 (1) , 38-45
Abstract
Parasympathetic activity influences long-term outcome in patients with cardiovascular disease, but the underlying mechanism(s) linking parasympathetic activity and the occurrence of major adverse cardiovascular events (MACEs) are incompletely understood. The aim of this pilot study was to evaluate the association between serum cholinesterase activities as parasympathetic biomarkers and the risk for the occurrence of MACEs. Cholinergic status was determined by measuring the cumulative capacity of serum acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) to hydrolyze the AChE substrate acetylthiocholine. Cholinergic status was evaluated in randomly selected patients undergoing cardiac catheterization. The patients were divided into two groups of 100 patients in each group, with or without occurrence of MACEs during a follow-up period of 40 months. Cox regression models adjusted for potential clinical, metabolic and inflammatory confounders served to evaluate association with clinical outcome. We found that patients with MACE presented lower cholinergic status and AChE values at catheterization (1,127 ± 422 and 359 ± 153 nmol substrate hydrolyzed per minute per milliliter, respectively) than no-MACE patients (1,760 ± 546 and 508 ± 183 nmol substrate hydrolyzed per minute per milliliter, p < 0.001 and p < 0.001, respectively), whose levels were comparable to those of matched healthy controls (1,622 ± 303 and 504 ± 126 nmol substrate hydrolyzed per minute per milliliter, respectively). In a multivariate analysis, patients with AChE or total cholinergic status values below median showed conspicuously elevated risk for MACE (hazard ratio 1.85 [95% confidence interval [CI] 1.09-3.15, p = 0.02] and 2.21 [95% CI 1.22-4.00, p = 0.009]) compared with those above median, even after adjusting for potential confounders. We conclude that parasympathetic dysfunction expressed as reduced serum AChE and AChE activities in patients compared to healthy controls can together reflect impaired parasympathetic activity. This impairment predicts the risk of MACE up to 40 months in such patients. Monitoring these parasympathetic parameters might help in the risk stratification of patients with cardiovascular disease.Keywords
This publication has 42 references indexed in Scilit:
- Impact of Estimated Glomerular Filtration Rate on Vascular Disease Extent and Adverse Cardiovascular Events in Patients Without Chronic Kidney DiseaseCanadian Journal of Cardiology, 2013
- Alteration of the microRNA network during the progression of Alzheimer's diseaseEMBO Molecular Medicine, 2013
- Stress-induced epigenetic transcriptional memory of acetylcholinesterase by HDAC4Proceedings of the National Academy of Sciences, 2012
- Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important LigandsJournal of Medicinal Chemistry, 2012
- Hippocampal microRNA-132 mediates stress-inducible cognitive deficits through its acetylcholinesterase targetBrain Structure and Function, 2012
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Structural Study of the Complex Stereoselectivity of Human Butyrylcholinesterase for the Neurotoxic V-agentsJournal of Biological Chemistry, 2011
- Quantum Dot Labeling of Butyrylcholinesterase Maintains Substrate and Inhibitor Interactions and Cell Adherence FeaturesACS Chemical Neuroscience, 2010
- Relation of Heart Rate Parameters During Exercise Test to Sudden Death and All-Cause Mortality in Asymptomatic MenThe American Journal of Cardiology, 2008
- The Protein Data BankNucleic Acids Research, 2000